Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.42 |
| ▸ | SRC | P12931 | 10/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665104 | 1.00 | ABL1 (0.49) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL24665075 | 1.00 | ABL1 (0.49) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL29978221 | 1.00 | ABL1 (0.49) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL24665103 | 1.00 | ABL1 (0.49) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL29977455 | 1.00 | ABL1 (0.49) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL24666964 | 0.93 | ABL1 (0.41) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL29977725 | 0.93 | ABL1 (0.41) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL24666787 | 0.93 | ABL1 (0.41) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL24666963 | 0.93 | ABL1 (0.41) | ABL1FGFR1SRCFGFR4KRAS | |
| SCHEMBL29977676 | 0.93 | ABL1 (0.41) | ABL1FGFR1SRCFGFR4KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |